[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343567-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343567-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immunotherapy-vaccines-for-prostate-cancer-treatment","Immunotherapy Vaccines for Prostate Cancer Treatment","","Therapeutic tumor vaccines represent a promising immunotherapy strategy for advanced prostate cancer, especially for patients experiencing biochemical relapse or who cannot undergo surgery. A structured review consolidates evidence from PubMed, Web of Science, Embase, and Scopus through August 31, 2024, covering dendritic cell-based, antigen, nucleic acid, and tumor cell vaccine approaches. Findings indicate favorable safety with limited adverse effects and clinically meaningful activity measured by PSA responses, PSA doubling time, survival outcomes, biochemical relapse rates, and antigen-specific immune responses. The review highlights formulation and deployment complexity and supports combining vaccines with other therapies while prioritizing earlier intervention and clarification of immune mechanisms in oncogenesis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immunotherapy-vaccines-for-prostate-cancer-treatment/343567/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immunotherapy-vaccines-for-prostate-cancer-treatment/343567.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the primary focus of therapeutic tumor vaccines for prostate cancer?","Question",{"text":63,"@type":64},"They aim to generate anti-tumor immune responses to reduce recurrence and metastasis in patients with advanced prostate cancer, including those with biochemical relapse or not eligible for surgery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were studies selected and what vaccine types were included?",{"text":68,"@type":64},"The review searched PubMed, Web of Science, Embase, and Scopus up to August 31, 2024 and included dendritic cell-based, antigen, nucleic acid, and tumor cell vaccines.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes suggest therapeutic benefit in the reviewed studies?",{"text":72,"@type":64},"Evidence reported favorable safety with few adverse effects and activity using metrics such as PSA response rates, PSA doubling times, overall survival, biochemical relapse rates, and antigen-specific immune responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343567,1790106065,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Medicine  \n| \u003Cbr> REVIEW  OPEN ACCESS \u003Cbr>Immunotherapy Vaccines for Prostate Cancer Treatment\u003Cbr>Jide He1 | Jialong Wu1 | Ziang Li1 | Zhenkun Zhao1 | Lei Qiu1 | Xuehua Zhu1 | Zenan Liu1 | Haizhui Xia1 | Peng Hong1  Jianling Yang2 | Ling Ni3  | Jian Lu1,4 \u003Cbr>1Department of Urology, Peking University Third Hospital, Beijing, China | 2Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China | 3Institute for Immunology and School of Medicine, Tsinghua University, Medical Research Building, Beijing, China | 4State Key Laboratory of Natural and Biomimetic Drugs, Peking University\u003Cbr>Correspondence: Ling Ni ([lingni@tsinghua.edu.cn](lingni@tsinghua.edu.cn)) | Jian Lu ([lujian@bjmu.edu.cn](lujian@bjmu.edu.cn))\u003Cbr>Received: 24 July 2024 | Revised: 9 September 2024 | Accepted: 21 September 2024\u003Cbr>Funding: This work was supported by the Natural Science Foundation of Beijing Municipality (No. L212051, No. Z200027), the National Natural Science Foundation of China (No. 62331001), and the Department of Science & Technology of Shandong Province (No. ZR2022ZD36) .\u003Cbr>Keywords: immunotherapy | prognosis | prostate cancer | therapeutic tumor vaccine | tumor treatment |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Background: Therapeutic tumor vaccines have emerged as a compelling avenue for treating patients afflicted with advanced prostate cancer (PCa), particularly those experiencing biochemical relapse or ineligible for surgical intervention. This study serves to consolidate recent research findings on therapeutic vaccines targeting prostate tumors while delineating prevalent challenges within vaccine research and development.\u003Cbr>Methods: We searched electronic databases, including PubMed, Web of Science, Embase, and Scopus, up to August 31, 2024, using keywords such as 'vaccine', 'prostate cancer', 'immunotherapy', and others. We reviewed studies on various therapeutic vaccines, including dendritic cell-based, antigen, nucleic acid, and tumor cell vaccines.\u003Cbr>Results: Studies consistently showed that therapeutic vaccines, notably DC vaccines, had favorable safety profiles with few adverse effects. These vaccines, with varied antigenic formulations, demonstrated strong clinical outcomes, as indicated by metrics such as PSA response rates (9.5%-58%), extended PSA doubling times (52.9%–89.7%), overall survival durations (17.7– 33.8 months), two-year mortality rates (0%–12.5%), biochemical relapse rates (42%–73%), and antigen-specific immune responses (33.3%–71.4% in responsive groups) .\u003Cbr>Conclusion: While clinical data for tumor vaccines have illuminated robust evidence of tumoricidal activity, the processes of their formulation and deployment are riddled with complexities. Combining vaccines with other therapies may enhance outcomes, and future research should focus on early interventions and deciphering the immune system's role in oncogenesis. |  |\n| 1 | Introduction | prevalent malignant epithelial tumor within the human urinary system, manifests a notable sensitivity to androgens during its |\n| Across the globe, the incidence of prostate cancer (PCa) demon- | initial stages of development. While early intervention through |\n| strates an escalating trend annually. Notably in China, there is | androgen-targeted therapy yields favorable outcomes for patients |\n| a steady rise in reported cases of PCa, accentuated by the re- | encountering advanced PCa or those ineligible for surgical re- |\n| curring instances of biochemical recurrence (BCR) observed | section, its efficacy diminishes in the progression to castration- |\n| each year. This concerning pattern has garnered attention from | resistant prostate cancer (CRPC) . This transition renders |\n| the Chinese Government [1–4] . PCa recognized as the most | traditional therapies, including chemotherapy, less effective, |\n| Jide He and Jialong Wu contributed equally to this manuscript. |  |\n| This is an open access article under the terms of the Creative Comm","cbCaiezvHMxsGOAw","https://ap.wps.com/l/cbCaiezvHMxsGOAw","pdf",2260200,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Epidemiology and clinical rationale\n## Limitations of current treatments\n## Concept of tumor vaccines and immune mechanisms","[{\"question\":\"What is the primary focus of therapeutic tumor vaccines for prostate cancer?\",\"answer\":\"They aim to generate anti-tumor immune responses to reduce recurrence and metastasis in patients with advanced prostate cancer, including those with biochemical relapse or not eligible for surgery.\"},{\"question\":\"How were studies selected and what vaccine types were included?\",\"answer\":\"The review searched PubMed, Web of Science, Embase, and Scopus up to August 31, 2024 and included dendritic cell-based, antigen, nucleic acid, and tumor cell vaccines.\"},{\"question\":\"What outcomes suggest therapeutic benefit in the reviewed studies?\",\"answer\":\"Evidence reported favorable safety with few adverse effects and activity using metrics such as PSA response rates, PSA doubling times, overall survival, biochemical relapse rates, and antigen-specific immune responses.\"}]","Immunotherapy Vaccines for Prostate Cancer Treatment | PDF",1790051447,33]